New study finds that lung cancer risk was increased after lung transplantation, particularly in the native (non-transplanted) lung of single lung transplant recipients. The findings of the study are published in the journal American Journal of Transplantation.
This was a large registry-linkage study that utilized matched transplant and cancer registry data from 17 US states/regions, including approximately 50 percent of US transplant recipients from 1987-2012.
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
Advertisement
‘A new study finds that lung transplant recipients have a higher risk of lung cancer that is poorly understood.’
Read More..
Tweet it Now
Read More..
Researchers found that patients with a single lung transplant had a 13-fold increased risk of lung cancer in the native lung compared with similar persons without a lung transplant in the general population.
Risk factors for the development of lung cancer in the native lung included those typically associated with lung cancer (older age, prior to smoking, and pulmonary fibrosis), as well as longer time since transplantation.
![Lung Cancer]( "Lung Cancer")
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with symptoms like recurrent respiratory diseases.
Compared with cases in the general population, lung cancers in transplant recipients were more frequently of a localized stage and were treated surgically; however, recipients had higher all-cause and cancer-specific mortality.
"Lung cancer is the most common cancer (except for skin cancers) to arise after lung transplant, and this study is one of the first to quantify that risk, examine risk factors, and explore survival in the lung transplant population using a large national cohort," said lead author Dr. Matthew Triplette, of the Fred Hutchinson Cancer Research Center and the University of Washington, in Seattle. "These findings have important implications in understanding long-term risks among lung transplant recipients."
Source: Eurekalert
Lung Cancer
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with symptoms like recurrent respiratory diseases.
Advertisement
Compared with cases in the general population, lung cancers in transplant recipients were more frequently of a localized stage and were treated surgically; however, recipients had higher all-cause and cancer-specific mortality.
"Lung cancer is the most common cancer (except for skin cancers) to arise after lung transplant, and this study is one of the first to quantify that risk, examine risk factors, and explore survival in the lung transplant population using a large national cohort," said lead author Dr. Matthew Triplette, of the Fred Hutchinson Cancer Research Center and the University of Washington, in Seattle. "These findings have important implications in understanding long-term risks among lung transplant recipients."
Source: Eurekalert
Common Blood Pressure Tablets May Increase Risk of Lung Cancer
A common blood pressure drug belonging to the class angiotensin-converting enzyme inhibitors (ACEI) can increase the risk of lung cancer. The risk increases after 5 years of use of ACEIs, which peaks after 10 years.
Advertisement
 Thermal Ablation as a First Step in Treating Early-stage Lung CancerLung cancer treatment using thermal ablation is a safe and effective option compared to radiation for patients with early-stage lung cancer who cannot undergo surgery, says study. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.